Trial ID or NCT#



recruiting iconRECRUITING


In this randomized controlled crossover study, the investigators propose to test the hypothesis that proton pump inhibitors (PPIs) increase plasma levels of asymmetric dimethylarginine (ADMA), which is a marker of endothelial dysfunction. The authors propose to evaluate ADMA concentrations and vascular function analysis in healthy volunteers and adults with a history of cardiovascular disease given PPI vs placebo for four weeks each.

Official Title

Do Proton Pump Inhibitors (PPIs) Increase Cardiovascular Risk? Effect of PPIs on Endothelial Function and ADMA.

Eligibility Criteria

Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes


Nicholas Leeper
Nicholas Leeper
Cardiologist, Vascular medicine specialist
Professor of Surgery (Vascular Surgery)

Contact us to find out if this trial is right for you.


Fouzia Khan
(650) 736-1410